Cogstate (ASX:CGS) - Hisse Senedi Fiyatı, Haberler ve Analizler

CGS Stoklara Genel Bakış

CGS temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	5/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 75.6% daha düşük bir oranda işlem görüyor

Kazançların yılda 6.63% oranında artması öngörülüyor

Kazançlar geçen yıl 52.8% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

CGS risk kontrollerimizi geçti.

Cogstate Limited Rakipler

SDI

ASX:SDI

AU$127.8m

Pacific Smiles Group

ASX:PSQ

AU$312.0m

SILK Laser Australia

ASX:SLA

AU$177.4m

Austco Healthcare

ASX:AHC

AU$91.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Cogstate
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.99
52 Haftanın En Yüksek Seviyesi	AU$1.56
52 Haftanın En Düşük Seviyesi	AU$0.80
Beta	0.091
11 Aylık Değişim	8.79%
3 Aylık Değişim	-14.66%
1 Yıllık Değişim	-32.19%
33 Yıllık Değişim	-57.33%
5 Yıllık Değişim	147.50%
Halka arzdan bu yana değişim	98.00%

Son Haberler & Güncellemeler

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Aug 30

Recent updates

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Aug 30

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

Jul 26

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Mar 23

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

Mar 02

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Jan 13

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Oct 04

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Sep 28

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Sep 02

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Jun 30

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

Mar 22

We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

Oct 20

Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital

Jul 23

Is Cogstate (ASX:CGS) Using Too Much Debt?

Apr 29

What Can The Trends At Cogstate (ASX:CGS) Tell Us About Their Returns?

Mar 14

Here's What Cogstate Limited's (ASX:CGS) Shareholder Ownership Structure Looks Like

Feb 21

How Much Is Cogstate's (ASX:CGS) CEO Getting Paid?

Jan 17

Can You Imagine How Jubilant Cogstate's (ASX:CGS) Shareholders Feel About Its 214% Share Price Gain?

Dec 05

Hissedar Getirileri

	CGS	AU Healthcare Services	AU Pazar
7D	2.6%	2.7%	-0.07%
1Y	-32.2%	121.0%	16.9%

Getiri vs. Endüstri: CGS geçen yıl % 121 oranında getiri sağlayan Australian Healthcare Services sektörünün gerisinde kaldı.

Getiri vs Piyasa: CGS geçen yıl % 16.9 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CGS's price volatile compared to industry and market?
CGS volatility
CGS Average Weekly Movement	7.7%
Healthcare Services Industry Average Movement	8.2%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.4%

İstikrarlı Hisse Senedi Fiyatı: CGS son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: CGS 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1999	160	Brad O'Connor	www.cogstate.com

Bir nörobilim teknolojisi şirketi olan Cogstate Limited, hem akademik hem de endüstri destekli araştırmalarda kullanılan dijital beyin sağlığı değerlendirmelerinin oluşturulması, doğrulanması ve ticarileştirilmesi ile ilgilenmektedir. Bilişsel hizmetleri arasında proje yönetimi, veri yönetimi, bilimsel danışmanlık, istatistiksel analiz, ölçek tedariki, puanlayıcı eğitimi ve izleme çözümleri bulunmaktadır. Şirket, geleneksel beyin sağlığı değerlendirmelerinin uygulanması, puanlanması ve kaydedilmesine odaklanan klinik çalışmalarda kalite güvence hizmetlerinin tasarımı ve sağlanmasında yer almaktadır.

Cogstate Limited Temel Bilgiler Özeti

Cogstate'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CGS temel i̇stati̇sti̇kler
Piyasa değeri	AU$170.92m
Kazançlar(TTM)	AU$8.44m
Gelir(TTM)	AU$67.27m

20.2x

F/K Oranı

2.5x

P/S Oranı

CGS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CGS gelir tablosu (TTM)
Gelir	US$43.43m
Gelir Maliyeti	US$19.13m
Brüt Kâr	US$24.30m
Diğer Giderler	US$18.85m
Kazançlar	US$5.45m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.032
Brüt Marj	55.96%
Net Kâr Marjı	12.55%
Borç/Özkaynak Oranı	0.3%

CGS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CGS Stoklara Genel Bakış

Ödüller

Risk Analizi

Cogstate Limited Rakipler

ASX:SDI

AU$127.8m

ASX:PSQ

AU$312.0m

ASX:SLA

AU$177.4m

ASX:AHC

AU$91.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Cogstate Appoints Kaycee Sink as Chief Medical Officer

CEO, MD & Executive Director exercised options to buy AU$965k worth of stock.

New minor risk - Market cap size

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Non-Executive Chairman recently bought AU$108k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations

Recent updates

Cogstate Appoints Kaycee Sink as Chief Medical Officer

CEO, MD & Executive Director exercised options to buy AU$965k worth of stock.

New minor risk - Market cap size

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Non-Executive Chairman recently bought AU$108k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations

Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus revenue estimates decrease by 10%, EPS upgraded

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

If EPS Growth Is Important To You, Cogstate (ASX:CGS) Presents An Opportunity

First half 2024 earnings released: EPS: US$0.012 (vs US$0 in 1H 2023)

Price target decreased by 8.1% to AU$1.70

Investor sentiment deteriorates as stock falls 17%

The Price Is Right For Cogstate Limited (ASX:CGS)

Cogstate Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 8.6% to AU$1.85

Cogstate Limited Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Is Cogstate Limited (ASX:CGS) Trading At A 29% Discount?

Now 21% undervalued

Price target decreased by 9.0% to AU$1.70

Now 23% undervalued

Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023

Consensus EPS estimates increase by 12%

Returns Are Gaining Momentum At Cogstate (ASX:CGS)

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

Investor sentiment deteriorates as stock falls 16%

CEO, MD & Executive Director recently bought AU$100k worth of stock

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

First half 2023 earnings released: EPS: US$0 (vs US$0.024 in 1H 2022)

Consensus EPS estimates increase by 23%, revenue downgraded

Investor sentiment deteriorates as stock falls 25%

Now 24% undervalued

Cogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023

Now 22% undervalued

Cogstate Limited Announces Resignation of David Dolby as Non-Executive Director

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Price target decreased to AU$1.92

High number of new and inexperienced directors

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Price target decreased to AU$2.18

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$2.41

Cogstate Limited Provides Earnings Guidance for the Fiscal Year 2023

High number of new and inexperienced directors

Price target decreased to AU$2.43

Investor sentiment improved over the past week

High number of new and inexperienced directors

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Cogstate Announces Formation of Scientific Advisory Board

Consensus EPS estimates fall by 82%

Investor sentiment improved over the past week

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

First half 2022 earnings: Revenues and EPS in line with analyst expectations